Evolus Shares Earn 'Moderate Buy' Rating from Analysts

Analysts see potential in the aesthetic medicine company despite recent stock price declines.

Published on Mar. 2, 2026

Got story updates? Submit your updates here. ›

Shares of Evolus, Inc. (NASDAQ:EOLS) have earned an average recommendation of "Moderate Buy" from the seven analysts currently covering the company, according to Marketbeat.com. While one analyst has rated the stock a "sell" and another a "hold", five have assigned a "buy" recommendation, with an average 1-year target price of $17.50.

Why it matters

Evolus is a specialty pharmaceutical company focused on the fast-growing medical aesthetics market. Its flagship product, Jeuveau, is a neuromodulator approved by the FDA for use in facial aesthetics procedures. The company's stock performance and analyst ratings provide insight into investor sentiment and the market's outlook for Evolus and its products.

The details

The analysts' ratings come after a period of stock price declines for Evolus. The company's shares have fallen from a 52-week high of $14.94 to a current price of around $4.25, a drop of over 70%. Factors contributing to the stock's decline include increased competition in the neuromodulator market and concerns over the company's financial performance.

  • Evolus shares have traded between $4.09 and $14.94 over the past 52 weeks.
  • The company's average stock price over the past 200 trading days is $6.28.

The players

Evolus, Inc.

A specialty pharmaceutical company focused on the medical aesthetics market, headquartered in Newport Beach, California.

Jeuveau

Evolus' flagship neuromodulator product approved by the FDA for facial aesthetics procedures.

Got photos? Submit your photos here. ›

What they’re saying

“We must not let individuals continue to damage private property in San Francisco.”

— Robert Jenkins, San Francisco resident (San Francisco Chronicle)

“Fifty years is such an accomplishment in San Francisco, especially with the way the city has changed over the years.”

— Gordon Edgar, grocery employee (Instagram)

The takeaway

While Evolus' stock has faced challenges, the 'Moderate Buy' rating from analysts suggests they see potential in the company's aesthetic medicine offerings. The market's assessment of Evolus will likely depend on the company's ability to navigate competition and improve its financial performance.